Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16835469 | 0.91 | CYP11B2 (0.51) | USP2SMN1; SMN2DDB1CRBNCYP11B2 | |
| SCHEMBL14297530 | 0.91 | USP2 (0.45) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL1707967 | 0.88 | GPR119 (0.45) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL346995 | 0.86 | USP2 (0.56) | USP2SMN1; SMN2GPR119CYP11B2ACACB | |
| SCHEMBL1707965 | 0.86 | GPR119 (0.44) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL904136 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL16401476 | 0.85 | ACACB (0.42) | USP2SMN1; SMN2DDB1CRBNCYP11B2 | |
| SCHEMBL16835515 | 0.85 | CYP11B2 (0.46) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL22836300 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL21285082 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2GPR119DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624019-B2 | Indazole derivative, and preparation method therefor and use thereof | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4698544-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | CELGENE CORPORATION (US) | 2026-01-29 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113417-A1 | Substituted Spiroamine Compounds | GRUENENTHAL GMBH (DE) | 2010-05-06 | — | — | US | disclosed |
| WO-2010046109-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | disclosed |
| US-20090227613-A1 | Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors | NEURO SEARCH A/S (DK) | 2009-09-10 | — | — | US | disclosed |
| US-20090036477-A1 | Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1899301-A1 | NOVEL 3-AZA-SPIROÝ5.5¨UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-03-19 | — | — | EP | disclosed |
| EP-1899303-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007000465-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000464-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDEC-8-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | USP2 740/4885SMN1; SMN2 1781/4885GPR119 1443/4885 |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | USP2 1713/4885SMN1; SMN2 1897/4885GPR119 2448/4885 |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | IRAK3, IRAK2, IRAK1 | USP2 682/4885SMN1; SMN2 1043/4885GPR119 1849/4885 |
| US-20090227613-A1 | Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | USP2 1709/4885SMN1; SMN2 1598/4885GPR119 187/4885 |
| US-20260041686-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS | CCR2, CCR1, CCRL2 | USP2 2365/4885SMN1; SMN2 1993/4885GPR119 446/4885 |
| US-20100113417-A1 | Substituted Spiroamine Compounds | BDKRB1, BDKRB2, REN | USP2 4868/4885SMN1; SMN2 2529/4885GPR119 686/4885 |
| US-12624019-B2 | Indazole derivative, and preparation method therefor and use thereof | IRAK4, IRAK1, IRAK2 | USP2 1262/4885SMN1; SMN2 3470/4885GPR119 1395/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | USP2 684/4885SMN1; SMN2 960/4885GPR119 932/4885 |
| US-20090036477-A1 | Novel 3-Aza-Spiro[5,5]Undec-8-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | USP2 2198/4885SMN1; SMN2 2236/4885GPR119 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.